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 Recent studies have linked patient misunderstanding of label instructions for as 
needed (PRN) medications to dosing errors. This study conducted a preliminary field 
test of patient-centered PRN label instructions. Patients participated in a hypotheti-
cal dosing experiment and were randomized to a patient-centered label (referred to 
as “Take-Wait-Stop”) or standard label. Participants were asked to demonstrate 
dosing the medicine over 24 hours. Three types of independent dosing errors were 
measured: (a) taking more than two pills at one time, (b) exceeding the maximum 
daily dose, and (c) waiting fewer than 4 hours between doses. Generalized linear 
models were used to assess the association between label type, health literacy, and 
sociodemographic characteristics. Participants’ mean age was 39.8 years, 62.1% 
were female, 43.7% were White, and 72.4% had adequate literacy. Of participants, 
31.8% who were shown the standard label demonstrated taking in excess of 6 pills in 
24 hours compared with only 14.0% of participants who were shown the Take-Wait-
Stop label (p = .05). Overall, only 1 person demonstrated he would take more than 2 
pills in a single dose.  Of the standard label group, 20.5% demonstrated dosing inter-
vals of fewer than 4 hours compared with 23.3% of the Take-Wait-Stop label group 
(p = .75). In a multivariate model, participants who were exposed to the standard 
label were 2.5 times more likely to exceed the recommended maximum daily dose 
(95% CI [1.05, 7.70], p = .03). The Take-Wait-Stop label was beneficial in prevent-
ing participants from exceeding the maximum dose in 24 hours, although it did not 
significantly reduce other dosing errors. 
Recent studies have demonstrated a high prevalence of  patient confusion and unin-
tentional misuse with current labeling standards for as needed (i.e., PRN, which is 
abbreviation for the Latin “pro re nata,” meaning “as the circumstance arises”) medi-
cations (Shone, King, Doane, Wilson, & Wolf, 2011; Simon, 1999; Wolf  et al., 2012). 
Dosing errors and adverse drug events have been documented for both prescription 
and over-the-counter PRN medications (Shone et al., 2011; Simon, 1999). These 
studies show that patients frequently misinterpret the complex instructions associ-
ated with a PRN medication, resulting in wrong doses or incorrect frequencies (num-
ber of  times per day). In the settings of  adult acetaminophen use as well as pediatric 
cold medications such unintended dosing errors have even resulted in liver failure and 
deaths (Bower, Johns, Margolis, Williams, & Bell, 2007; Dart et al., 2009). 
The majority (77%) of prescription instructions for chronic medications describe 
fixed dosing intervals (i.e., two times daily; Institute of Medicine, 2008). Although 
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the public health goal for chronic medications is to promote routine use, the objective 
for PRN medications is to prevent routine use and overuse. PRN instructions require 
patients to actively participate in interpreting label instructions because the medica-
tion intended use is meant to be limited based on symptoms. This added complexity 
of PRN medication instructions intuitively makes the task of appropriately taking 
the prescribed drug more prone to errors resulting from misinterpretation; previous 
studies have demonstrated (in the chronic medication setting) that patients’ compre-
hension is improved with more explicit, deconstructed instructions (Davis et al., 2009; 
Wolf, Davis, et al., 2011). 
As part of ongoing research efforts to promote more patient-centered drug label-
ing across prescription medicines, we conducted a preliminary field test of a labeling 
strategy referred to as the “Take-Wait-Stop” method. This method is a patient-cen-
tered, PRN-specific set of label instructions developed by our team. Key components 
of patient-centered prescription label design have been previously described in the 
literature (National Council for Prescription Drug Programs, 2013; Sahm et al., 2012; 
Shrank et al., 2010; Wolf, Davis, et al., 2011). In accordance with these design tenets, 
we deconstructed the core components of PRN instructions and more explicitly con-
veyed (a) dose (number of pills per use), (b) interval (mandatory time between doses), 
and (c) maximum daily dose that is not to be exceeded. The emphasis on action terms 
(“Take-Wait-Stop”) was chosen to help frame each behavioral step and to serve as 
a mnemonic device supporting individuals’ ability to quickly understand and recall 
proper use of a PRN medicine. We hypothesized that patients viewing the Take-Wait-
Stop label would be less likely to make dosing errors.
 Method 
 Participants 
This study was part of a larger investigation of patients’ medication use after receiving 
a new prescription for an acetaminophen-containing analgesic medication. Between 
April and October 2011, patients receiving a prescription for an acetaminophen-con-
taining analgesic medicine were consecutively recruited from an emergency depart-
ment in a teaching hospital in Chicago, Illinois. This was a convenience sample, and 
patients were recruited during daytime hours on weekdays on the basis of the research 
assistant’s availability. Patients were deemed eligible to participate if  they (a) spoke 
English, (b) were 18 to 80 years of age, and (c) did not have psychological impair-
ment or intoxication (as judged by a trained research staff  member). Patients were pre-
scribed a pain medication containing acetaminophen. Patients were excluded if  they 
were admitted to the hospital or were receiving a refill of an acetaminophen-contain-
ing pain medication that they used chronically at home. After completion of the study, 
patients were compensated US$50. The Institutional Review Board at Northwestern 
University approved this study. 
 Procedure 
Patients who gave consent were instructed to return 4 to 7 days after initial recruit-
ment to complete an in-person interview about their use of  the new acetamin-
ophen-containing medication (results reported separately). The interview also 
included questions pertaining to basic demographic information (age, sex, race/
ethnicity), socioeconomic information (education, household income), health status 
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(self-reported overall health, number of  prescription medications, number of  over-
the-counter medications), and a literacy assessment. We used the Rapid Estimate of 
Adult Literacy in Medicine, a widely used and validated instrument for measuring 
health literacy (Davis et al., 1991). 
The investigators chose to conduct the pilot test of the patient-centered PRN label 
in this population in part because all of the patients had recent exposure to taking 
a PRN medication and their recollection of their recent (or ongoing) pain episode 
increased the fidelity of the pilot test. After they completed the demographic assess-
ment, participants were randomized to receive either the standard PRN label (Figure 
1A) or the patient-centered, Take-Wait-Stop label for a PRN medicine (Figure 1B) to 
test the efficacy of the Take-Wait-Stop label in improving accurate medication dos-
ing. The Take-Wait-Stop label design was based on previous research and included 
the explicit, deconstructed instructions along with simplified text, numeric characters 
instead of words (e.g., “1 tab” instead of “one tab”) and “carriage returns” to place 
 Figure 1. (A) Standard label; (B) patient-centered label (Take-Wait-Stop). 
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each part of the instructions on separate lines (Wolf, Davis, et al., 2011). In addi-
tion, to convey the maximum daily dosage to patients in plain language, the new label 
used the word Stop to replace the typical wording Do not exceed. This wording was 
chosen on the basis of previous qualitative research that found patients—particularly 
those with limited literacy skills—preferred this wording and felt that the word stop 
was easier to understand and pronounce than the word exceed (King et al., 2011). 
The core components of the instructions were deconstructed so that each action or 
intended behavior was separate and would potentially allow patients to be more cog-
nizant of each step to be taken. This deconstruction is supported by previous research 
that more explicit medication instructions (in non-PRN medications) improve patient 
understanding and is a health literacy best practice (Davis et al., 2009; Wolf, Davis, 
et al., 2011). 
To assess medication dosing, participants were presented with a dosing tray 
that contained 24 slots representing each hour of a day. Participants were given the 
hypothetical prescription bottle and instructed to place plastic pills into the slots to 
demonstrate how much and when they would take doses of the medication throughout 
the day. Our team has repeatedly used this approach to guide—and not lead—patients 
in documenting medication use (Wolf, Curtis, et al., 2011). 
Given that the medicines assessed in this activity were PRN, research assistants 
used the following standard script to ensure that patients would feel free to continue to 
redose for the full 24 hours rather than stopping at one dose so that the risk of misuse 
by either too narrow intervals between doses or exceeding the maximum dose could 
be fully assessed: 
 Please imagine that you have been prescribed this medicine for your pain. 
Using this container, I would like you to show me how you might take 
this medicine on a day you were having pain. 
So imagine that it is 8am and you are having pain. 
Please show me how many pills of this medicine you would take at 
8am by placing the beads into the box.
If  you were still in pain after taking this dose of medicine, when could 
you take this medicine again? 
Show me at what time and how many pills of this medicine you would 
take for your next dose. 
The final two prompts were repeated until reaching 24 hours or until the patient said 
that he or she would not take any additional pills.
 Outcomes 
The outcome of  interest was incorrect dosing of  the medication; this was measured 
in three ways. First, patients could incorrectly dose their medication by placing more 
than two pills into a single dose in the tray (dose error). Second patients could exceed 
the maximum daily dose if  they placed more than the recommended six pills into 
the dosing tray (max dose error). Third, patients could incorrectly dose the PRN 
medicine by not waiting a sufficient amount of  time between intervals (fewer than 
4 hours; timing error). Each of  these outcomes was independent, given that an indi-
vidual could take too much medication in a single dose, but then not take any addi-
tional pills throughout that day and therefore not exceed the maximum daily dose. 
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 Analysis Plan 
Descriptive statistics (percentage, mean and standard deviation) were calculated for 
demographic variables. Bivariate analyses were performed for each of the three out-
comes to assess whether patients’ performance differed on the task depending on the 
label to which they were exposed (standard vs. Take-Wait-Stop). Generalized linear 
models with a Poisson distribution and log link function with robust variance estimates 
were used for outcomes found to be statistically significant in the bivariate analysis to 
estimate prevalence ratios with 95% confidence intervals. We chose this approach as 
an odds ratio from logistic regression could overestimate associations due to the high 
percentage of responses falling in one category (Barros & Hirakata, 2003; Zou, 2004). 
Final models controlled for age, race (White, Black, other), and literacy level (adequate, 
limited). Results are reported as adjusted relative risk (RR). All statistical analyses were 
performed using STATA software version 12.1 (StataCorp, College Station, TX).
 Results 
We enrolled 87 participants in this field test. The majority of the sample was female 
(62.1%) and had adequate literacy (72.4%). In addition, the majority of the sample 
had been recently prescribed and had taken an acetaminophen-hydrocodone combi-
nation drug at home (93.1%). The other acetaminophen combination drugs recently 
prescribed to the sample included: acetaminophen-caffeine-butalbital and acetamin-
ophen-codeine. There were no statistically significant differences between the baseline 
characteristics of patients in the standard label group and the Take-Wait-Stop label 
group (Table 1).
The outcomes of the dosing activity by label type are shown in Table 2. Of the 
sample, 23% exceeded the maximum daily dose noted on the bottle and for this error 
type, there were statistically significant differences by study arm (standard label error 
rate = 31.8% vs. Take-Wait-Stop label error rate = 14%, p = .05). The mean number of 
tablets that patients exceeded the recommended dose by was 3.45 tabs (range = 1–13). 
The rate of errors related to medication timing (interval of fewer than 4 hours) was 
also high at 21.8%, but there were no differences in performance on the basis of label 
type. On average, patients who took the dose at an unsafe time interval were taking the 
dose 1.8 hours before the next safe dose was due. Only one person made the error of 
taking more than two pills per dose. 
After controlling for age, race, and literacy level, the relationship between label type 
and dosing errors remained statistically significant. Those exposed to the standard label 
were 2.5 times more likely to exceed the recommended maximum daily dose (95% CI 
[1.05, 7.70], p = .03). Black participants were also more likely to make maximum daily 
dose errors (RR 3.15, 95% CI [1.11, 8.93], p = .03), as well as participants whose race/
ethnicity was categorized as other (RR 4.88, 95% CI [1.57, 15.19], p = .006).  Neither age 
nor literacy skills were found to be independent predictors of dosing errors. 
 Discussion 
In our sample, nearly a quarter of participants demonstrated they would exceed the 
maximum daily dose of a prescribed PRN medication, and one in five dosed out the 
drug at too frequent time intervals. As an initial field test of a more patient-centered, 
explicitly worded labeling strategy for as-needed medicines, our findings suggest this 
approach could be a promising direction for improved labeling. Individuals who 
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received the Take-Wait-Stop label were significantly less likely to exceed the maximum 
daily dose. However, problems with waiting the appropriate amount of time between 
doses were not reconciled with this more explicit set of instructions, but they were also 
not worse than a current standard. 
The Take-Wait-Stop label worked best on untangling one common aspect of 
instructions —the maximum daily dose message—that may more likely be omitted or 
underemphasized in current labeling practices. Thus, the greatest benefit was found in 
reduced errors around exceeding the maximum daily dose. Given that only one patient 










 Age, M (SD) 39.8 (12.9) 40.1 (13.1) 39.4 (12.8) .79
Gender .31
 Male 37.9 43.2 32.6
 Female 62.1 56.8 67.4
Race .82
 White 43.7 45.5 41.9
 Black 40.2 40.9 39.5
 Other 16.1 13.6 18.6
Education .55
 High school or less 25.3 29.6 20.9
 Some college 33.3 34.1 32.6
 College graduate 41.4 36.4 46.5
Literacy .68
 Adequate 72.4 70.5 74.4
 Inadequate 27.6 29.6 25.6
Income .08
 Less than $20,000 26.4 22.7 30.2
 $20,000–50,000 29.9 40.9 18.6
 More than $50,000 43.7 36.4 51.2  
 Table 2.  Outcomes of dosing activity, by label type 
 Total 
(N = 87)




(n = 43) 
 Outcome n % n % n % p 
 Exceeded maximum dose 20 23.0 14 31.8 6 14.0 .05
More than two pills per dose 1 1.2 1 2.3 0 0.0 .47
Interval of fewer than 4 hr 19 21.8 9 20.5 10 23.3 .75 
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exceeded correct number of pills for a single dose, it is clear that this is not a primary 
source of confusion with label instructions, and it is understandable why our more 
explicit strategy did not affect this type of error. 
In addition, the Take-Wait-Stop approach did not significantly improve problems 
with errors related to spacing of doses as demonstration of intervals which were too 
narrow did not differ by label type. There are several possible reasons for this. The 
instructions for calculating dosing interval and maximum daily dose require some 
proficiency with basic math skills. Yet, patients with limited literacy, who would also 
disproportionately struggle with numeracy tasks, were not more likely to make these 
errors. As a seemingly simple behavior, it could be that without specific times of day 
stated, the more explicit Take-Wait-Stop instruction for dosing interval did not nota-
bly reduce the complexity of the task. In addition while this was a hypothetical sce-
nario, the framing around persistent pain could have elicited a need for a more imme-
diate response. Perhaps this is the most difficult challenge with PRN medicines—that 
safety information such as maximum daily dose can be conveyed to the patient, but 
how the medicine is used is ultimately in the hands of the patient experiencing symp-
toms. When patients experience symptoms and attempt to self-titrate the amount of 
medicine, their need for pain relief  may overtake their recall of instructions or con-
cerns about safety.
It is interesting that patients’ literacy level did not affect their performance on the 
task. As a field test, this study was not specifically powered to detect such differences 
and the lack of a difference may be because the patient sample to a large extent had 
adequate literacy. It is important to note that non-White race/ethnicity was associ-
ated with a greater risk of exceeding maximum daily dose. This could be related to 
language proficiency or cultural factors such as beliefs associated with medication 
risks (Bailey, Agarwal, Sleath, Gumusoglu, & Wolf, 2011; Bailey et al., 2009). It is 
unfortunate that our data limit our ability to truly understand the root cause of this 
finding. Other study limitations include the hypothetical nature of our outcome of 
demonstrated dosing errors and type; participants’ performance may not accurately 
represent their actual behavior at home. However, all patients enrolled had been taking 
an acetaminophen-based PRN analgesic before participating in the study and there-
fore had recent experience at home. Although in this context this is a strength, it is also 
a potential weakness because patients may have been prescribed a different analgesic 
and therefore may have been performing the task based on the instructions for their 
home medication. 
On closer review of the actual medications patients were taking to determine their 
potential influence on the results, we found that none of the prescriptions had dosing 
intervals of more than 4 hours and none recommended taking more than two pills 
per dose. Further, only one bottle had a warning about maximum daily dose on the 
primary label, and less than half  (44%) had auxiliary warning labels on the bottle stat-
ing a maximum daily dose in milligrams. Therefore, the presence of a maximum daily 
dose warning, and providing this information in number of pills (vs. milligrams), was 
new to patients. Thus, it is unlikely that actual medication use negatively influenced 
performance on these hypothetical tasks.
Overall, we found that patients taking PRN prescription medications frequently 
make dosing errors, and the use of the Take-Wait-Stop strategy significantly reduced 
those associated with maximum daily dose. Future directions should (a) improve how 
a Take-Wait-Stop approach can better communicate all aspects of proper dosing and 
(b) conduct a larger trial of this approach in actual use. 
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